Telbivudine

Drugs

Volumn 67, Issue 13, 2007, Pages 1917-1929

  Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALAMIFOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B; CLEVUDINE; CYCLOSPORIN; EMTRICITABINE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; LOOP DIURETIC AGENT; PEGINTERFERON ALPHA2A; PLATINUM DERIVATIVE; TELBIVUDINE; TENOFOVIR; TORCITABINE; TYZEKA; UNCLASSIFIED DRUG; VANCOMYCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HEPATITIS B; HUMAN; MONOTHERAPY; MYOPATHY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRUS LOAD;

ANTIVIRAL AGENTS; DNA-DIRECTED DNA POLYMERASE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; PYRIMIDINONES;

HEPATITIS B VIRUS;

EID: 34548346918     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767130-00011     Document Type: Review

References (49)

1. Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J 2006 Feb; 36 (2): 100-13
2. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 Oct; 45 (4): 529-38
3. European Medicines Agency. Sebivo: scientific discussion. [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/sebivo/H-713- en6.pdf [Accessed 2007 May 19]
4. Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs 2006; 66 (12): 1605-22; discussion 1623-4
5. Buti M, Esteban R. Drugs in development for hepatitis B. Drugs 2005; 65 (11): 1451-60
6. Ganem D, Prince AM. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med 2004 Mar 11; 350 (11): 1118-29
7. Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005; 25 Suppl. 1: 40-7
8. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 Jan 4; 295 (1): 65-73
9. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006 Mar; 130 (3): 678-86
10. Robins GW, Scott LJ, Keating GM. Peginterferon-α-2a (40kD): a review of its use in the management of patients with chronic hepatitis B. Drugs 2005; 65 (6): 809-25
11. Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis B [published erratum appears in Drugs 1999; 58: 587]. Drugs 1999 Jul; 58 (1): 101-41
12. Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003; 63 (20): 2215-34
13. Bryant ML, Bridges EG, Placidi L, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001 Jan; 45 (1): 229-35
14. Standring DN, Bridges EG, Placidi L, et al. Antiviral β-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001; 12 Suppl. 1: 119-29
15. European Medicines Agency. Sebivo 600mg film-coated tablets: summary of prescribing information [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/sebivo/H-713-PI-en.pdf [Accessed 2007 May 19]
16. Seifer M, Patty A, Dukhan D et al. Telbivudine (LDT) preferentially inhibits second (+) strand HBV DNA synthesis [abstract no. M935]. Gastroenterology 2005 May 16; 128 (4 Suppl. 2): 742-43. Plus poster presented at Digestive Disease Week; 2005 May 14-19; Chicago (IL)
17. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005 Aug; 129 (2): 528-36
18. Bridges EG, Juodawlkis A, Faraj A, et al. Antiviral activity of β-L-thymidine and β-L-2′deoxycytidine in the woodchuck model of chronic hepatitis B infection [abstract no. 91]. Antiviral Res 2000 Jan; 46 (1): 62
19. Delaney WEIV, Yang H, Miller MD, et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004 Oct; 48 (10): 3702-10
20. Lai CL, Leung NW, Teo EK, et al. Phase IIb extended-treatment trial of telbivudine vs lamivudine vs combination treatment in hepatitis B patients: two-year results [abstract no 320]. Gastroenterology 2005 Apr; 128 (4 Suppl. 2): A692
21. Seifer M, Patty A, Chapron C, et al. Genotypic analysis of patients with evaluable HBV DNA after 1 year of telbivudine therapy in the GLOBE Registration Trial [abstract no. 93]. Digestive Disease Week; 2007 May 19-24; Washington DC
22. Standring DN, Patty A, Chapron C, et al. Resistance determination in patients experiencing virologic breakthrough following telbivudine or lamivudine therapy in the international GLOBE trial [abstract no. S1781 plus poster]. Digestive Disease Week; 2007 May 19-24; Washington DC
23. Standring DN, Seifer M, Patty A, et al. HBV resistance determination from the telbivudine GLOBE registration trial [abstract no. 514]. J Hepatol 2006; 44 (2 Suppl.): S191
24. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10 (5): 625-33
25. Idenix Pharmaceuticals Inc. Tyzeka (telbivudine) tablets. US prescribing information [online]. Available from URL: https://www.tyzeka.com/pdf/ TYZEKA_PI_11-3-06_TYZ_MPI_02_001.pdf [Accessed 2007 Jul 29]
26. Hu P, Jiang J, Wang H, et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J Clin Pharmacol 2006 Sep; 46 (9): 999-1007
27. Lai CL, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004 Sep; 40 (3): 719-26
28. Zhou XJ, Lloyd DM, Chao GC, et al. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol 2006 Mar; 46 (3): 275-81
29. Zhou XJ, Fielman B, Dubuc-Patrick G, et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and peginterferon alpha-2a or cyclosporine in healthy subjects [abstract no. 522]. J Hepatol 2006; 44 Suppl. 2: S194
30. Zhou XJ, Fielman BA, Lloyd DM, et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother 2006 Jul; 50 (7): 2309-15
31. Zhou X, Pietropaolo K, Becker M, et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and tenofovir [abstract no. 1782 plus poster]. Digestive Disease Week; 2007 May 19-24; Washington DC
32. Zhou XJ, Lim SG, Lloyd DM, et al. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother 2006 Mar; 50 (3): 874-9
33. Zhou XJ, Myers M, Chao G, et al. Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function [abstract no. 1166]. Hepatology 2004 Oct; 40 (4 Suppl. 1): 672
34. Zhou XJ, Marbury TC, Alcorn HW, et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother 2006 May; 50 (5): 1721-6
35. Data on file. Novartis Pharmaceuticals Corporation, 2007
36. Lai C-L, Gane E, Liaw Y-F, et al. Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) [abstract no. 92]. Hepatology 2005 Oct; 42 (4 Suppl. 1): 232A-3A. Plus oral presentation at The Liver Meeting; 2005 Nov 11-15; San Francisco (CA)
37. Bzowej N, Lai C, Gane E, et al. Phase III comparison of telbivudine vs lamivudine in patients with chronic hepatitis B: efficacy, safety, and predictors of response at 1 year [abstract no. 482]. Gastroenterology 2006 Apr; 130 (4 Suppl. 2): A765-A766. Plus oral presentation at Digestive Disease Week; 2006 May 20-25; Los Angeles (CA)
38. Rasenack J, Poynard T, Lai C-L, et al. Efficacy of telbivudine vs lamivudine at 2 years in patients with HBeAg-positive chronic hepatitis B who are eligible for treatment based on guidelines [abstract plus poster]. 42nd Annual Meeting of the European Association for the Study of the Liver; 2007 Apr 11-15; Barcelona
39. Poynard T, Chutaputti A, Hwang SG, et al. Sustained off-treatment HBeAg response in telbivudine and lamivudine treated HBeAg-positive patients from the GLOBE study [abstract]. 42nd Annual Meeting of the European Association for the Study of the Liver; 2007 Apr 11-15; Barcelona
40. Han S, Lai C, Gane E, et al. Telbivudine GLOBE trial at year two: efficacy, safety, and predictors of outcome in patients with chronic hepatitis B [abstract no. S1777 plus poster]. Digestive Disease Week; 2007 May 19-24; Washington DC
41. Gane E, Lai C-L, Min A, et al. Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the GLOBE study [abstract and poster]. 42nd Annual Meeting of the European Association for the Study of the Liver; 2007 Apr 11-15; Barcelona
42. Jia JD, Hou JL, Yin YK, et al. The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52 [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2007 May; 15 (5): 342-5
43. Wang Y, Jia J, Hou J, et al. A phase III comparative trial of telbivudine vs lamivudine in Chinese patients with chronic hepatitis B: two-year results [abstract no. S1768 plus poster]. Digestive Disease Week; 2007 May 19-24; Washington DC
44. Safadi R, Xie Q, Chen Y, et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24 [abstract plus poster]. 42nd Annual Meeting of the European Association for the Study of the Liver; 2007 Apr 11-15; Barcelona
45. Bzowej N, Marcellin P, Chan H, et al. A randomized trial of telbivudine vs adefovir for HBeAg-positive chronic hepatitis B: efficacy through week 76, predictors of response and effects of switching to telbivudine [abstract no. S1774 plus poster]. Digestive Disease Week; 2007 May 19-24; Washington DC
46. Marcellin P, Chan HLY, Lai C-L, et al. 76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine [abstract]. 42nd Annual Meeting of the European Association for the Study of the Liver; 2007 Apr 11-15; Barcelona
47. Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism? Drug Saf 2000 Dec; 23 (6): 467-81
48. GlaxoSmithKline Research. Epivir-HBV® (lamivudine). US prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/ us_epivir_hbv.pdf [Accessed 2007 Jul 29]
49. Gilead Sciences Inc. Hepsera® (adefovir dipivoxil). US prescribing information [online]. Available from URL: http://www.hepsera.com/pdf/GIL214- 07_Hepsera_PDF.8.pdf [Accessed 2007 Jul 29]